Impact of Government Grants on Venture Capital Funding of Deep Technology University Spinoffs

2019 ◽  
Author(s):  
Andrea Belz ◽  
Fernando Zapatero
Keyword(s):  
Venture Capital ◽  
Government Grants ◽  
Venture Capital Funding ◽  
Capital Funding ◽  
University Spinoffs

Trademarks and Venture Capital Funding

2012 ◽  
Author(s):  
Joern Hendrich Block ◽  
Geertjan de Vries ◽  
Philipp G. Sandner ◽  
Jan H. Schumann
Keyword(s):  
Venture Capital ◽  
Venture Capital Funding ◽  
Capital Funding

Start A Fire: Creating Value and Growth

2019 ◽  
pp. 1-16
Author(s):  
Sarit Markovich ◽  
Oded Golan ◽  
Charlotte Snyder
Keyword(s):  
Social Media ◽  
Venture Capital ◽  
Media Management ◽  
Conference Room ◽  
Tel Aviv ◽  
Management Platform ◽  
Venture Capital Funding ◽  
Capital Funding ◽  
Social Media Management ◽  
A Company

In March 2017, Oded Golan sat in his technology startup's conference room with his co-founder, pondering the fate of their company, Start A Fire. In just four years, the two entrepreneurs had taken an idea that started in Golan's apartment in Tel Aviv and turned it into a company that had raised $3.5 million in venture capital funding and served more than 3,000 of the world's biggest brands using an innovative content distribution and social media management platform that enabled brands to improve communication and engagement with their followers

Patent strategies for life sciences companies to navigate the changing patent landscape

1969 ◽  
Vol 17 (4) ◽  
Author(s):  
David J Dykeman ◽  
Danielle T Abramson
Keyword(s):  
Intellectual Property ◽  
Venture Capital ◽  
New Products ◽  
Life Sciences ◽  
Venture Capital Funding ◽  
Patent Landscape ◽  
Capital Funding ◽  
The Us ◽  
Life Sciences Industry ◽  
Patent Portfolio

As a result of the global recession that began in 2008, life sciences companies face a groundswell of new business and regulatory pressures that includes health care and patent reform, increased pricing pressures, and diluted markets. Bringing new products from discovery to market is becoming more expensive and unpredictable. In the pharmaceutical sector, some predict that the age of the blockbuster drug has ended as generics present a growing threat to the pharmaceutical giants. Further, with a large number of key patent expirations looming through 2014, analysts expect that large pharmaceutical companies will lose over US$150 billion of revenues of brand name drugs.In response to declining sales and rising R&D costs, the life sciences industry is pursuing new market opportunities by expanding beyond the developed markets of the United States, Europe and Japan, and into emerging markets such as China and India. Despite market uncertainties, however, venture capital funding in the life sciences sector (including pharmaceuticals and medical devices) is on the rise with $2.1 billion going into 206 deals during the second quarter of 201l, an increase of 37 per cent in dollars and 12 per cent in deal volume. To survive – and thrive – in these tumultuous times, both large and small life sciences companies face pressure to develop new products and technological advancements.Patents are pivotal to the life sciences industry. In order to succeed, life sciences companies must distinguish themselves from their competitors through their intellectual property portfolios. A successful patent portfolio represents a well-reasoned business strategy, where each patent is a single strategic building block in a larger portfolio that reflects present and future business objectives. A strong patent portfolio is also important in the current life sciences investment climate, where venture capital funding is often dependent on whether a company has secured its intellectual property assets, thereby validating a company's technology and demonstrating its commercial potential. Although building and maintaining a strong patent portfolio is important for all life sciences companies, it is most critical for early-stage companies. Patent portfolios are often the driving force for major events in the life cycle of a life sciences company, including mergers and acquisitions, public offerings, venture capital investment, strategic collaborations, joint ventures and litigation.As a result of recent measures taken by the US Congress, the US Patent and Trademark Office (USPTO) and the US Supreme Court to reform the current US patent system, life sciences companies must respond with strong patent strategies that address these reforms without sacrificing the company's competitive edge in the marketplace. Such comprehensive technology strategies must maximize patent coverage of a company's current core technology and future improvements, monitor the patent landscape and explore ways to patent white space, and consider cross-licensing opportunities with competitors. With these strategies in place, life sciences companies can withstand patent reform and ensure their success in today's competitive and rapidly evolving global commercialization landscape.

Sign in / Sign up

Export Citation Format

Share Document